Miguel A. Villalona‐Calero

Author

Also Known As

Dancey, Janet, M A Villalona-Calero, M Villalona-Calero, M. A. Villalona-Calero, M. Villalona-Calero, M.A. Villalona-Calero, Miguel A Villalona-Calero, Miguel A. Villalona-Calero, Miguel A. Villalona‐Calero, Miguel Angel Villalona-Calero

352

Publications

Citations

H-Index

Concepts

All Affiliations

The Ohio State University The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute The University of Texas Health Science Center at San Antonio National Cancer Institute The Ohio State University Wexner Medical Center

About

Miguel A. Villalona‐Calero is an author at The Ohio State University specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	48	2.4K
2	Health Sciences	6	6	434
3	Natural Sciences	3	3	372
4	Biochemistry	2	2	109
5	Engineering	1	1	28

Miguel A. Villalona‐Calero

109

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Natasha B. Leighl, Ray D. Page, Victoria M. Raymond, Clinical Cancer Research	2019	584
Clinical response and <i>miR-29b</i> predictive significance in older AML patients treated with a 10-day schedule of decitabine William Blum, Ramiro Garzon, Rebecca B. Klisovic, Proceedings of the National Academy of Sciences	2010	453
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer Elaine T. Lam, Matthew D. Ringel, Richard T. Kloos, Journal of Clinical Oncology	2010	373
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers Tanios Bekaii‐Saab, Mitch A. Phelps, Xiaobai Li, Journal of Clinical Oncology	2011	301
Methylation of Adjacent CpG Sites Affects Sp1/Sp3 Binding and Activity in the <i>p21<sup>Cip1</sup></i> Promoter Wei‐Guo Zhu, Kanur Srinivasan, Zunyan Dai, Molecular and Cellular Biology Histone ModificationsEpigenetic ChangeGeneticsDna MethylationMolecular Biology	2003	259
Efficacy and safety of crizotinib in patients with advanced <i>c-MET</i>-amplified non-small cell lung cancer (NSCLC). D. Ross Camidge, Sai‐Hong Ignatius Ou, Geoffrey I. Shapiro, Journal of Clinical Oncology PathologyPharmacotherapyPre-clinical PharmacologyMolecular PharmacologyMetronomic Therapy	2014	256
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial Pasi A. Jänne, Xiaofei Wang, Mark A. Socinski, Journal of Clinical Oncology	2012	249
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease Thomas S. Lin, Amy S. Ruppert, Amy J. Johnson, Journal of Clinical Oncology	2009	222
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology Don S. Dizon, Lada Krilov, Ezra E.W. Cohen, Journal of Clinical Oncology MedicineCancer ManagementPathologyAmerican SocietyClinical Oncology	2016	212
Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301 Antonius A. Miller, Daryl J. Murry, Kouros Owzar, Journal of Clinical Oncology	2009	207

Page 1